Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ: CRVS · IEX Real-Time Price · USD
0.870
-0.230 (-20.91%)
At close: Jun 24, 2022 4:00 PM
1.020
+0.150 (17.241%)
After-hours: Jun 24, 2022 7:59 PM EDT

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year 20212020201920182017201620152014
Selling, General & Admin
9.5211.9310.8810.6410.227.622.420.12
Research & Development
29.1231.8337.9838.5946.3129.3611.350.04
Operating Expenses
38.6343.7648.8549.2256.5236.9813.770.16
Operating Income
-38.63-43.76-48.85-49.22-56.52-36.98-13.77-0.16
Other Expense / Income
4.61-37.77-2.18-2.28-0.86-0.617.570
Pretax Income
-43.24-6-46.67-46.94-55.66-36.38-31.34-0.16
Net Income
-43.24-6-46.67-46.94-55.66-36.38-31.34-0.16
Net Income Common
-43.24-6-46.67-46.94-55.66-36.38-31.34-0.16
Shares Outstanding (Basic)
42292928201500
Shares Outstanding (Diluted)
42292928201500
Shares Change
41.98%0.44%6.69%34.27%32.85%4027.48%119.43%-
EPS (Basic)
-1.03-0.20-1.59-1.71-2.72-2.36-83.86-0.95
EPS (Diluted)
-1.03-0.20-1.59-1.71-2.72-2.36-83.86-0.95
Free Cash Flow Per Share
-0.88-1.18-1.27-1.50-2.27-1.95-34.99-0.56
EBITDA
-42.78-5.36-45.93-46.09-54.82-35.78-31.19-0.16
Depreciation & Amortization
0.460.630.740.850.840.590.150
EBIT
-43.24-6-46.67-46.94-55.66-36.38-31.34-0.16
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).